Menu
Enrolling by invitation NCT07316582

Melatonin Loaded in Injectable Platelet-Rich Fibrin in the Management Periodontitis

Phase IV Interventional Periodontitis Stage II

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Melatonin-Loaded Injectable Platelet-Rich Fibrin, injectible platelet rich fibrin (i-PRF ).
Who it may be relevant to
Registry conditions: Periodontitis Stage II. Basic parameters: 20 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Clinical and Biochemical Evaluation of Melatonin Loaded in Injectable Platelet-Rich Fibrin in the Management of Stage II Grade A Periodontitis: A Randomized Controlled Clinical Trial

Overview

melatonin loaded in injectible platelet rich fibrin in treatment of periodontitis

Interventions

  • Drug Melatonin-Loaded Injectable Platelet-Rich Fibrin
    patients will be included in this group receiving SRP with Melatonin loaded in (I-PRF) using insulin syringe for injection
  • Biological injectible platelet rich fibrin (i-PRF )
    patients will be included in this group receiving (SRP) with local application of i-PRF

Primary outcome measures

  • Clinical attachment level (CAL) [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

\- Diagnosed with stage II periodontitis based on AAP/EFP 2018 classification

  • Minimum of two non-adjacent periodontal pockets <5 mm in different quadrants
  • Systemically healthy individuals willing to participate and comply with follow-up visits
  • Radiographic bone loss (ranged from is 10-20% mostly horizontal

Exclusion criteria

History of systemic diseases affecting periodontium (e.g., diabetes, osteoporosis)

  • Use of antibiotics, anti-inflammatories, or antioxidant supplements in the past 3 months
  • Smoking or tobacco use
  • Pregnancy or lactation
  • Allergy to melatonin or related compounds

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Faculty of Dental Medicine for girls Al-Azhar University — New Cairo

Identifiers

NCT: NCT07316582 · P-ME-25-16

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗